Cell Therapy Human Raw Materials Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Stage

Description

The global cell therapy human raw materials market is projected to grow from $5.2 billion in 2025 to $20.9 billion by 2035, at a compound annual growth rate (CAGR) of 15.0%. The cell therapy human raw materials market comprises suppliers of growth factors, cytokines, cell culture media, sera, buffers, reagents, supplements, and other materials used throughout cell therapy development and manufacturing. The market includes global and specialized suppliers serving biotechnology and pharmaceutical companies, research organizations, and cell therapy manufacturers. Growth factors, cytokines, and culture media represent important product categories because they support cell expansion, differentiation, activation, and survival. Competition includes established life sciences companies and specialized raw material providers, with companies emphasizing product quality, consistency, regulatory compliance, and manufacturing scalability. For instance, in February 2026, BioLife Solutions announced a multi-year supply agreement with Qkine to distribute cytokine and growth factor products for cell and gene therapy manufacturing.

Based on product, growth factors are the dominant segment in the cell therapy human raw materials market. Growth factors are essential components used to regulate cell proliferation, differentiation, survival, and functionality during cell culture and expansion. Their application spans multiple cell therapy workflows, including stem cell development, immune cell manufacturing, regenerative medicine, and oncology research. Growth factors are incorporated into specialized culture media and manufacturing processes to support consistent cell growth and maintain desired cellular characteristics. Their broad applicability across different cell types and therapeutic development stages contributes to their significant role within the overall demand for human raw materials used in cell therapy manufacturing.

Market Segmentation
Type	Autologous, Allogeneic, Xenogeneic, Syngeneic, Others
Product	Growth Factors, Cytokines, Serum-Free Media, Fetal Bovine Serum, Human Serum, Buffers, Reagents, Supplements, Others
Services	Cell Culture Services, Cell Banking Services, Cell Characterization Services, Cell Processing Services, Quality Control Services, Others
Technology	CRISPR, Gene Editing, Stem Cell Technology, CAR-T Cell Therapy, Induced Pluripotent Stem Cells (iPSCs), Others
Component	Primary Cells, Stem Cells, Differentiated Cells, Others
Application	Oncology, Cardiovascular, Neurology, Orthopedic, Wound Healing, Ophthalmology, Immunology, Others
Process	Cell Expansion, Cell Isolation, Cell Cryopreservation, Cell Differentiation, Cell Transfection, Others
End User	Biopharmaceutical Companies, Research Institutes, Contract Research Organizations, Hospitals, Clinics, Others
Stage	Preclinical, Clinical, Commercial, Others

Based on technology, CRISPR is the fastest-growing segment in the cell therapy human raw materials market. CRISPR technology enables precise genetic modification of cells and supports the development of engineered cell therapies with targeted therapeutic characteristics. Its applications include modifying immune cells, improving cellular functionality, and developing experimental treatments for cancer and genetic disorders. The technology is increasingly incorporated into research and cell therapy development workflows that require controlled gene modification. Its compatibility with advanced cell engineering approaches, including stem cell and immune cell applications, supports expanding utilization of specialized raw materials such as culture media, reagents, enzymes, and supplements throughout CRISPR-based cell therapy development.

Geographical Overview

North America is the largest region in the cell therapy human raw materials market, supported by an established biotechnology ecosystem, extensive cell therapy research, and a strong presence of pharmaceutical and biopharmaceutical companies. The United States represents the major contributor within the region, with substantial activity in cell therapy development, clinical research, and commercial manufacturing. Canada also contributes through its biotechnology sector, research institutions, and cell therapy initiatives. The region benefits from established manufacturing capabilities, specialized suppliers of cell culture materials and reagents, and a developed research infrastructure supporting the use of human raw materials across cell therapy development and production.

Asia-Pacific is the fastest-growing region in the cell therapy human raw materials market, supported by expanding biotechnology capabilities, increasing investments in advanced therapies, and the development of cell therapy manufacturing infrastructure. China, Japan, South Korea, and Australia are among the important markets, with growing research and clinical development activities. Increasing participation of pharmaceutical and biotechnology companies in cell-based therapy development is creating demand for growth factors, cytokines, media, reagents, and other specialized materials. The expansion of research institutions, clinical trial activity, and manufacturing capabilities is further supporting the adoption of cell therapy raw materials across the region.

Key Trends and Drivers

Increasing Adoption of Automation and Advanced Cell Processing Technologies

The cell therapy human raw materials market is witnessing increasing adoption of automation and advanced cell processing technologies across research and manufacturing workflows. Automated cell culture, media preparation, cell expansion, and processing systems are being integrated to improve process consistency, reproducibility, and scalability. These technologies require standardized and high-quality growth factors, cytokines, media, reagents, and supplements that can perform consistently within controlled manufacturing environments. The development of automated and closed processing platforms is also supporting more efficient handling of therapeutic cells and strengthening requirements for reliable raw material quality. This trend is shaping supplier strategies toward products compatible with increasingly standardized and scalable cell therapy manufacturing processes.

Growing Development Of Cell-Based Therapies

The growing development of cell-based therapies is driving demand for human raw materials required throughout research, development, and manufacturing activities. Pharmaceutical and biotechnology companies are advancing cell therapies across oncology, regenerative medicine, immunology, cardiovascular, neurological, and orthopedic applications, increasing the need for specialized materials that support cell isolation, expansion, differentiation, activation, and preservation. The expansion of clinical and commercial cell therapy pipelines is consequently creating broader requirements for growth factors, cytokines, serum-free media, reagents, supplements, and other processing materials. Increasing efforts to establish scalable manufacturing processes further strengthen demand for consistent, high-quality raw materials that can support reproducible cell production across different therapeutic programs.

Research Scope

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

Product Code: GIS26943

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by Process
2.7 Key Market Highlights by End User
2.8 Key Market Highlights by Stage
2.9 Key Market Highlights by Component

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Autologous
- 4.1.2 Allogeneic
- 4.1.3 Xenogeneic
- 4.1.4 Syngeneic
- 4.1.5 Others
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Growth Factors
- 4.2.2 Cytokines
- 4.2.3 Serum-Free Media
- 4.2.4 Fetal Bovine Serum
- 4.2.5 Human Serum
- 4.2.6 Buffers
- 4.2.7 Reagents
- 4.2.8 Supplements
- 4.2.9 Others
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Cell Culture Services
- 4.3.2 Cell Banking Services
- 4.3.3 Cell Characterization Services
- 4.3.4 Cell Processing Services
- 4.3.5 Quality Control Services
- 4.3.6 Others
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 CRISPR
- 4.4.2 Gene Editing
- 4.4.3 Stem Cell Technology
- 4.4.4 CAR-T Cell Therapy
- 4.4.5 Induced Pluripotent Stem Cells (iPSCs)
- 4.4.6 Others
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Oncology
- 4.5.2 Cardiovascular
- 4.5.3 Neurology
- 4.5.4 Orthopedic
- 4.5.5 Wound Healing
- 4.5.6 Ophthalmology
- 4.5.7 Immunology
- 4.5.8 Others
4.6 Market Size & Forecast by Process (2020-2035)
- 4.6.1 Cell Expansion
- 4.6.2 Cell Isolation
- 4.6.3 Cell Cryopreservation
- 4.6.4 Cell Differentiation
- 4.6.5 Cell Transfection
- 4.6.6 Others
4.7 Market Size & Forecast by End User (2020-2035)
- 4.7.1 Biopharmaceutical Companies
- 4.7.2 Research Institutes
- 4.7.3 Contract Research Organizations
- 4.7.4 Hospitals
- 4.7.5 Clinics
- 4.7.6 Others
4.8 Market Size & Forecast by Stage (2020-2035)
- 4.8.1 Preclinical
- 4.8.2 Clinical
- 4.8.3 Commercial
- 4.8.4 Others
4.9 Market Size & Forecast by Component (2020-2035)
- 4.9.1 Primary Cells
- 4.9.2 Stem Cells
- 4.9.3 Differentiated Cells
- 4.9.4 Others

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 Process
  - 5.2.1.7 End User
  - 5.2.1.8 Stage
  - 5.2.1.9 Component
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 Process
  - 5.2.2.7 End User
  - 5.2.2.8 Stage
  - 5.2.2.9 Component
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 Process
  - 5.2.3.7 End User
  - 5.2.3.8 Stage
  - 5.2.3.9 Component
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 Process
  - 5.3.1.7 End User
  - 5.3.1.8 Stage
  - 5.3.1.9 Component
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 Process
  - 5.3.2.7 End User
  - 5.3.2.8 Stage
  - 5.3.2.9 Component
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 Process
  - 5.3.3.7 End User
  - 5.3.3.8 Stage
  - 5.3.3.9 Component
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 Process
  - 5.4.1.7 End User
  - 5.4.1.8 Stage
  - 5.4.1.9 Component
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 Process
  - 5.4.2.7 End User
  - 5.4.2.8 Stage
  - 5.4.2.9 Component
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 Process
  - 5.4.3.7 End User
  - 5.4.3.8 Stage
  - 5.4.3.9 Component
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 Process
  - 5.4.4.7 End User
  - 5.4.4.8 Stage
  - 5.4.4.9 Component
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 Process
  - 5.4.5.7 End User
  - 5.4.5.8 Stage
  - 5.4.5.9 Component
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 Process
  - 5.4.6.7 End User
  - 5.4.6.8 Stage
  - 5.4.6.9 Component
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 Process
  - 5.4.7.7 End User
  - 5.4.7.8 Stage
  - 5.4.7.9 Component
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 Process
  - 5.5.1.7 End User
  - 5.5.1.8 Stage
  - 5.5.1.9 Component
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 Process
  - 5.5.2.7 End User
  - 5.5.2.8 Stage
  - 5.5.2.9 Component
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 Process
  - 5.5.3.7 End User
  - 5.5.3.8 Stage
  - 5.5.3.9 Component
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 Process
  - 5.5.4.7 End User
  - 5.5.4.8 Stage
  - 5.5.4.9 Component
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 Process
  - 5.5.5.7 End User
  - 5.5.5.8 Stage
  - 5.5.5.9 Component
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 Process
  - 5.5.6.7 End User
  - 5.5.6.8 Stage
  - 5.5.6.9 Component
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 Process
  - 5.6.1.7 End User
  - 5.6.1.8 Stage
  - 5.6.1.9 Component
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 Process
  - 5.6.2.7 End User
  - 5.6.2.8 Stage
  - 5.6.2.9 Component
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 Process
  - 5.6.3.7 End User
  - 5.6.3.8 Stage
  - 5.6.3.9 Component
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 Process
  - 5.6.4.7 End User
  - 5.6.4.8 Stage
  - 5.6.4.9 Component
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 Process
  - 5.6.5.7 End User
  - 5.6.5.8 Stage
  - 5.6.5.9 Component

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Lonza
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Thermo Fisher Scientific
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Merck KGaA
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Sartorius
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Corning Incorporated
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Fujifilm Holdings Corporation
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Miltenyi Biotec
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 STEMCELL Technologies
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Bio-Techne Corporation
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Takara Bio
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 GE Healthcare
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Becton Dickinson and Company
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Danaher Corporation
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Charles River Laboratories
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 PeproTech
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 PromoCell
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 CellGenix
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Stemcell Technologies
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Wuxi AppTec
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 RoosterBio
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us